Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Treatment of Bladder Cancer After Platinum and PD-1/L1 Inhibitor Therapy: Real-World Outcomes

By: Gavin Calabretta, BS
Posted: Tuesday, November 16, 2021

Recent findings published in Future Oncology suggest that patients with locally advanced or metastatic urothelial carcinoma tend to have a short duration of real-world survival outcomes following platinum and PD-1/L1 inhibitor therapy. According to Katherine Tan, PhD, of Flatiron Health, New York, and colleagues, the study represents the largest real-world data set on survival in this population to date .

Study data were collected from the Flatiron Health nationwide electronic health record–derived U.S. oncology database, which encompasses more than 280 cancer clinics. The study population comprised two cohorts: patients treated with taxane monotherapy (n = 72) and patients who received any therapy post PD-1/L1 inhibitor treatment (n = 208). In both cohorts, patients had to have had prior platinum-containing chemotherapy and PD-1/L1 inhibitor therapy to be eligible.

In the taxane-monotherapy cohort, median real-world overall survival was 7.6 months (95% confidence interval [CI] = 5.2–14.4 months), and the 6-month survival probability was rated at 56% (95% CI = 45–70%). The median real-world progression-free survival was 2.9 months (95% CI = 2.4–4.0 months), and the 6-month real-world progression-free survival probability was 26% (95% CI = 17–40%). In comparison, the any-therapy cohort had a median real-world overall survival of 8.9 months (95% CI = 7.3-10.6 months) and a 6-month survival probability of 63% (95% CI = 56–71%). The median real-world progression-free survival was 3.6 months (95% CI = 2.7–4.7 months), and the 6-month real-world progression-free survival probability was 37% (95% CI = 30–45%).

“Among patients who do receive subsequent therapy, real-world outcomes, as determined by real-world progression-free survival and real-world overall survival, are poor,” the study authors commented. “Novel and effective therapeutic options should be considered in this patient population,” they concluded.   

Disclosure: For full disclosures of the study authors, visit futuremedicine.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.